Drug Profile
Research programme: immunological disorder therapeutics - Ondek
Alternative Names: ImmBALANCE®; OND 86Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Ondek
- Class Allergy immunotherapies; Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Atopic dermatitis; Food hypersensitivity
- No development reported Eczema; Hypersensitivity; Inflammation
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Allergy(Prevention) in Australia (PO)
- 11 Sep 2020 Research programme: immunological disorder therapeutics is still in preclinical development in Allergy in Australia (PO) (Ondek pipeline September 2020)
- 11 Sep 2020 No development reported - Preclinical for Eczema (In children) in Australia (PO) (Ondek pipeline September 2020 )